tiprankstipranks
Trending News
More News >
Certara (CERT)
NASDAQ:CERT
US Market

Certara (CERT) Earnings Dates, Call Summary & Reports

Compare
225 Followers

Earnings Data

Report Date
Aug 12, 2025
TBA Not Confirmed
Period Ending
2025 (Q2)
Consensus EPS Forecast
0.09
Last Year’s EPS
0.07
Same Quarter Last Year
Moderate Buy
Based on 9 Analysts Ratings

Earnings Call Summary

Earnings Call Date:May 05, 2025
|
% Change Since: -7.98%
|
Next Earnings Date:Aug 12, 2025
Earnings Call Sentiment|Positive
The earnings call presented a generally positive outlook for Certara, driven by strong revenue and bookings growth, the launch of new software versions, and the FDA's announcement favoring their product offerings. While market headwinds and specific segment softness were noted, the company's strategic initiatives and new opportunities seemed to outweigh the challenges.
Company Guidance
During Certara's First Quarter 2025 Earnings Conference Call, significant guidance was provided detailing the company's financial performance and future outlook. Certara reported first-quarter revenue of $106 million, reflecting a 10% increase from the same period in 2024. Bookings for the quarter were $118.2 million, up 12% year-over-year, with software bookings growing by 23% and services bookings by 7%. Chemaxon significantly contributed $5.9 million to revenue and $4.9 million to bookings. The guidance for the full year anticipates total revenue between $415 million and $425 million, with Chemaxon expected to contribute $23 million to $25 million. Adjusted EBITDA margins are projected to be between 30% and 32%, with adjusted EPS in the range of $0.42 to $0.46. Certara emphasized strategic investments in AI integration and biosimulation model development, particularly in response to the FDA's recent move to phase out animal testing, which is expected to positively impact the company's future growth trajectory.
Strong Revenue and Bookings Growth
Certara reported first quarter revenue of $106 million, representing a 10% growth compared to Q1 2024. Bookings reached $118.2 million, a 12% increase from the previous year.
Significant Software Segment Performance
Software revenue for Q1 2025 was $46.4 million, an 18% increase from the prior year, with software bookings growing by 23%. Chemaxon contributed $5.9 million to software revenue.
FDA Announcement on Animal Testing Phase-Out
The FDA's announcement to phase out animal testing has led to significant interest in Certara's Non-Animal Navigator solution, which leverages AI and modeling to replace animal testing in drug development.
Launch of Simcyp Simulator Version 24
Certara announced the 24th version of its Simcyp Simulator, featuring new drug interaction libraries and enhanced modeling capabilities. Simcyp has supported over 120 FDA-approved novel drug applications.
Share Repurchase Program
Certara announced a $100 million share repurchase authorization, with approximately $25 million repurchased to date, reflecting confidence in the company's long-term growth strategies.
Adjusted EBITDA Growth
Adjusted EBITDA for Q1 2025 was $34.8 million, up from $29.1 million in Q1 2024, with a margin of 33%.

Certara (CERT) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

CERT Earnings History

Report Date
Fiscal Quarter
Forecast / EPS
Last Year's EPS
EPS YoY Change
Press Release
Slides
Play Transcript
Aug 12, 2025
2025 (Q2)
0.09 / -
0.07
May 05, 2025
2025 (Q1)
0.11 / 0.14
0.140.00% (+0.04)
Feb 26, 2025
2024 (Q4)
0.12 / 0.15
0.0966.67% (+0.06)
Nov 06, 2024
2024 (Q3)
0.11 / 0.13
0.1118.18% (+0.02)
Aug 06, 2024
2024 (Q2)
0.10 / 0.07
0.12-41.67% (-0.05)
May 07, 2024
2024 (Q1)
0.10 / 0.10
0.12-16.67% (-0.02)
Feb 29, 2024
2023 (Q4)
0.11 / 0.09
0.16-43.75% (-0.07)
Nov 08, 2023
2023 (Q3)
0.11 / 0.11
0.110.00% (<+0.01)
Aug 09, 2023
2023 (Q2)
0.13 / 0.12
0.0933.33% (+0.03)
May 08, 2023
2023 (Q1)
0.12 / 0.12
0.119.09% (<+0.01)
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed

CERT Earnings-Related Price Changes

Report Date
Price 1 Day Before
Price 1 Day After
Percentage Change
May 05, 2025
$12.78$11.37-11.03%
Feb 26, 2025
$12.33$12.40+0.57%
Nov 06, 2024
$10.91$10.99+0.73%
Aug 06, 2024
$15.08$13.03-13.59%
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Certara (CERT) report earnings?
Certara (CERT) is schdueled to report earning on Aug 12, 2025, TBA Not Confirmed.
    What is Certara (CERT) earnings time?
    Certara (CERT) earnings time is at Aug 12, 2025, TBA Not Confirmed.
      Where can I see when companies are reporting earnings?
      You can see which companies are reporting today on our designated earnings calendar.
        What companies are reporting earnings today?
        You can see a list of the companies which are reporting today on TipRanks earnings calendar.
          What is CERT EPS forecast?
          CERT EPS forecast for the fiscal quarter 2025 (Q2) is 0.09.
            What am I Missing?
            Make informed decisions based on Top Analysts' activity
            Know what industry insiders are buying
            Get actionable alerts from top Wall Street Analysts
            Find out before anyone else which stock is going to shoot up
            Get powerful stock screeners & detailed portfolio analysis